Viekira Pak

Showing 6 posts of 6 posts found.

msd

MSD’s Zepatier approval could spell end of Gilead’s Hep C dominance, says analyst

February 10, 2016
Sales and Marketing AbbVie, Drug pricing, Gilead Sciences, MSD, Solvadi, Viekira Pak, harvoni, hepatitis C

The introduction of MSDs’ recently FDA-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market …

abbvie

AbbVie posts strong Q4 results

February 1, 2016
Sales and Marketing AbbVie, Humira, Viekira Pak

AbbVie managed to meet or beat analysts’ expectations in its Q4 financial results report, with extremely strong Humira sales contributing …

Logos

New regulatory submissions for AbbVie and Novo Nordisk

December 4, 2015
Medical Communications AbbVie, EMA, FDA, Novo Nordisk, Viekira Pak, insulin aspart

AbbVie and Novo Nordisk have submitted new drug applications to the US FDA and European Medicines Agency (EMA) respectively. The …

Abbvie image

AbbVie hep C drug gets priority review in Japan

April 16, 2015
Sales and Marketing AbbVie, EC, EU, Europe, Exviera, FDA, Japan, Viekira Pak, Viekirax, hepatitis C, ombitasvir/paritaprevir/ritonavir

AbbVie’s combination hepatitis C treatment looks set to be approved in yet another country after being granted priority review in …

Viekirax and Exviera image

AbbVie Hep C combo pill ready for Europe

January 16, 2015
Medical Communications AbbVie, Exviera, FDA, HIV, Viekira Pak, Viekirax, harvoni, hep C, sovaldi

The European Commission has approved AbbVie’s Viekirax and Exviera for the treatment of chronic hepatitis C (HCV). Viekirax (ombitasvir/paritaprevir/ritonavir) and …

Abbvie

Abbvie Hep C drug gains FDA approval

December 22, 2014
Sales and Marketing AbbVie, FDA, Gilead, Viekira Pak, dasabuvir, harvoni, hepatitis, hepatits C

Abbvie has gained sign-off for its rival treatment to challenge Gilead’s dominance of the growing market for new hepatitis C …

The Gateway to Local Adoption Series

Latest content